Cohort Description of Patients with Triple-Negative Basal-Like Subtype Breast Cancer Treated at the National Cancer Institute and the San José Hospital from 2006 to 2008
Keywords:
Breast neoplasms, keratins, immunohistochemistry, prevalenceAbstract
Objectives: To use immunohistochemistry to provide a description of and to ascertain the prevalence of clinical-pathological characteristics in patients with triple-negative (basal-like and non basal-like) subtype breast cancer treated at the National Cancer Institute (NCI) and the San José Hospital (SJH) from 2006 to 2008.
Methods: A descriptive cross sectional study was carried out among women over 17 years of age with confirmed diagnosis of breast adenocarcinoma. Patients whose paraffin blocks were not preserved and those on whom it was not possible to carry out the entirety of the immunohistochemical markers requisite for this study were excluded before collection of the immunohistochemical markers considered essential for this study (EFGR, CK5, CK6, S100, P65, CK 14) was performed. Samples were processed according to manufacturer's instructions; information was analyzed with Stata 10 software.
Results: A total of 1,922 invasive breast cancer cases were diagnosed from 2006 to 2008, 154 of which were triple-negative (ER negative, PR negative, HER-2 negative). Complete information was obtained in 84 of these cases: 50 cases (59.52%) were basal-like and 34 cases (40.48%) were non basal-like tumors.
Conclusions: This study, the first in Colombia which seeks to determine through immunohistochemistry the prevalence of triple-negative basal-like breast cancer in the Colombian population, found said tumor prevalence to be at 8.01%, which is below that reported in worldwide literature (11.9%-25%).
Author Biographies
Óscar García, Instituto Nacional de Cancerología
Clínica de Seno y Tejidos Blandos, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Carlos A. Ossa, Clínica Las Américas
Servicio de Cirugía de Seno, Clínica Las Américas, Medellín, Colombia
María I. Beltrán, Instituto Nacional de Cancerología
Departamento de Patología Oncológica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Miguel Cano, Fundación Universitaria Hospital San José
Servicio de Patología, Fundación Universitaria Hospital San José, Bogotá, D.C., Colombia
Licet Villamizar, Instituto Nacional de Cancerología
Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá, D. C., Colombia
Ana M. Arias, Clínica Colsubsidio
Servicio de Seno, Clínica Colsubsidio, Bogotá, D. C, Colombia
References
American Cancer Society. Overview: Breast Cancer [in- ternet]. 2006 [citado: 15/01/2012. Disponible en: http://www.cancer.org.
Ferlay J, Bray F, Pisan P, et al. International Agency for Research on Cancer. GLOBOCAN 2008. IARC. Cancer Database, No. 5, versión 2.
Instituto Nacional de Cancerología (INC). Anuario Estadístico 2008. Bogotá: INC; 2009.
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
https://doi.org/10.1038/35021093
Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-6.
https://doi.org/10.1038/415530a
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-502.
https://doi.org/10.1001/jama.295.21.2492
Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol. 2002;161:1991-6.
https://doi.org/10.1016/S0002-9440(10)64476-8
Rakha EA, Tan DS, Foulkes WD, et al. Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res. 2007;9:404.
https://doi.org/10.1186/bcr1827
Moll R, Krepler R, Franke WW. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation. 1983;23:256-69.
https://doi.org/10.1111/j.1432-0436.1982.tb01291.x
Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-71.
https://doi.org/10.1038/modpathol.3800528
Bosch A, Eroles P, Zaragoza R, et al. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 2010;36:206-15.
https://doi.org/10.1016/j.ctrv.2009.12.002
Wellings SR, Roberts P. Electron microscopy of sclerosing adenosis and infiltrating duct carcinoma of the human mammary gland. J Natl Cancer Inst. 1963;30:269-87.
Sarkar K, Kallenbach E. Myoepithelial cells in carcinoma of human breast. Am J Pathol. 1966;49:301-7.
Murad TM, Scharpelli DG. The ultrastructure of medullary and scirrhous mammary duct carcinoma. Am J Pathol. 1967;50:335-60.
Dairkee SH, Mayall BH, Smith Hs, et al. Monoclonal marker that predicts early recurrence of breast cancer. Lancet. 1987;1:514.
https://doi.org/10.1016/S0140-6736(87)92129-5
Malzahn K, Mitze M, Thoenes M, et al. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch. 1998;433:119-29.
https://doi.org/10.1007/s004280050226
Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 2006;49:22-34.
https://doi.org/10.1111/j.1365-2559.2006.02453.x
Rodríguez S, Sarrio D, Honrado E, et al, Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinoma. Clin Cancer Res. 2006;12:1533-9.
https://doi.org/10.1158/1078-0432.CCR-05-2281
Liedtke C, Mazouni CH, Kenneth RH, et al. Response to Neoadjuvant theraphy and long-term survival in patients with triple-negative. Breast Cancer JCO. 2008;26:1275-81.
https://doi.org/10.1200/JCO.2007.14.4147
Choi YL, Oh E, Park S, et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer. 2010;10:507.
https://doi.org/10.1186/1471-2407-10-507
Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236-
https://doi.org/10.1002/ijc.23518
Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, et al. Triple-negative breast cancer in hispanic patients: High prevalence, poor prognosis, and association with menopausal status, body mass index, and parity. Cancer. 2011;117:3658-69.
https://doi.org/10.1002/cncr.25961
Vallejos CS, Gómez HL, Cruz WR, et al. Breast cancer classification according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clinical Breast Cancer. 2010;10:294-300.
https://doi.org/10.3816/CBC.2010.n.038
De Brot M, Soares FA, Stiepcich M, et al. Basal-like breast cancers: clinicopathological features and outcome. Rev Assoc Med Bras. 2009;55:529-34.
https://doi.org/10.1590/S0104-42302009000500014
Choi YL, Oh E, Park S, et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer. 2010;10:507.
https://doi.org/10.1186/1471-2407-10-507
Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer. 2008;123:236-40.
https://doi.org/10.1002/ijc.23518
Kreike B, van kouwenhove M, Horlings H, et al. Gene expression profiling and histopathological of triple- negative/basal-like breast carcinoma. Breast Cancer Res. 2007;9:R65.
https://doi.org/10.1186/bcr1771
Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-74.
https://doi.org/10.1158/1078-0432.CCR-04-0220
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-48.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
